Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Prostate cancer
Phase II trial of JSB462 (novel androgen receptor antagonist) plus abiraterone in metastatic prostate cancer
This randomized, open-label, multi-center study by Novartis evaluates safety, efficacy, and pharmacokinetics of two JSB462 dosing regimens combined with standard abiraterone versus standard ARPIs in adult males with…
NCT06991556 Exploratory - New trial
Prostate cancer
Phase II Tumor-Focused Radiotherapy: Image-Guided Brachytherapy Radiation Device Targeting Prostate Cancer
The University of California, San Diego is conducting a phase II randomized trial comparing standard whole-prostate radiotherapy with investigational image-guided tumor-focused radiotherapy using a brachytherapy…
NCT06990542 Exploratory - New trial
Prostate cancer
Phase 1 Pilot: 225Ac-PSMA-617 alpha-emitter targeting PSMA in prostate cancer
This single-center pilot study compares 177Lu-PSMA-617 and 225Ac-PSMA-617 radioligand therapies administered via IV or intra-arterial routes in patients with localized high-risk prostate cancer scheduled for…
NCT07054346 Exploratory - New trial
Brain and CNS tumors
Phase 1b Definity: Microbubble ultrasound contrast agent for enhanced glioma visualization
This study evaluates DEFINITY UTZ contrast with contrast enhanced ultrasound during glioma surgery to determine if improved visualization can aid tumor resection. Patients with glioma will undergo surgery using this…
NCT07050836 Exploratory - New trial
Brain and CNS tumors
Phase I Trial of Triapine (Ribonucleotide Reductase Inhibitor) with Radiation for Recurrent Gliomas
This study evaluates the safety, side effects, and optimal dose of triapine in combination with daily intensity modulated radiation therapy for patients with recurrent diffuse midline gliomas, astrocytomas…
NCT06860594 Exploratory - New trial
Lymphoma
Phase I CCR4 CAR T Cells gene therapy targeting CCR4 in T-cell lymphomas
This Phase I trial by the National Cancer Institute tests the safety of administering autologous T cells engineered with an anti-CCR4 CAR. Eligible adults have CCR4+ peripheral or cutaneous T-cell lymphomas that are…
NCT07055477 First-in-human - New trial
Lymphoma
Phase I N-803 study of IL-15 agonist fusion protein in post-CAR T therapy
This Phase I trial seeks to determine the safety and tolerability of N-803, an IL-15 agonist fusion protein, administered as maintenance therapy following CD19-targeted CAR T-cell treatment for patients with relapsed…
NCT07049432 Exploratory - New trial
Lymphoma
Phase I/IB Ropeginterferon Trial Targeting Interferon A2b Protein in CTCL
This single-center study at H. Lee Moffitt Cancer Center is evaluating Ropeginterferon-alfa 2b, administered subcutaneously every 2 weeks at doses from 250 µg to 500 µg, to determine the recommended phase II dose in…
NCT07047885 Exploratory - New trial
Lymphoma
Phase II trial of axicabtagene ciloleucel, a CD19-targeted CAR T cell therapy
This randomized trial led by City of Hope Medical Center evaluates whether fecal microbiome transplantation (FMT) administered before and after standard leukapheresis, chemotherapy, and axicabtagene ciloleucel…
NCT07042438 Exploratory - New trial
Liver and bile duct cancer
Phase Ib/II Zanzalintinib Trial: cMet/VEGFR Inhibitor for Advanced Hepatocellular Carcinoma
This Phase Ib/II trial led by Northwestern University assesses zanzalintinib, a small molecule inhibitor of cMet and VEGFR, for safety, dose-finding, and preliminary effectiveness in patients with advanced…
NCT07042919 Exploratory - New trial
Liver and bile duct cancer
Phase 1 Feasibility Trial: Atezolizumab PD-L1 mAb & Bevacizumab VEGF mAb with Y90 Radioembolization
This single-institution, single-arm feasibility trial evaluates the combination of systemic atezolizumab (a PD-L1 targeting monoclonal antibody) and bevacizumab (a VEGF targeting monoclonal antibody) with…
NCT07059494 Exploratory - New trial
Colorectal cancer
Phase 1 Trial: HistoSonics Histotripsy (ultrasound cavitation tissue ablation) in advanced colorectal metastases
Investigating whether combining histotripsy with standard palliative chemotherapy improves progression-free survival in patients with unresectable, bilobar colorectal liver metastases, this prospective, single-arm…
NCT07044362 Exploratory - New trial
Colorectal cancer
Phase II trial of fruquintinib (VEGFR inhibitor) with 5FU-based therapy in advanced colorectal cancer
Conducted at Houston Methodist Neal Cancer Center, this Phase II trial evaluates the safety and efficacy of combining 5FU-based chemotherapy (FOLFIRI or mFOLFOX6) with fruquintinib, a VEGFR inhibitor, as a first-line…
NCT07042685 Exploratory - New trial
Kidney cancer
Phase II Zanzalintinib cMET/VEGFR inhibitor for metastatic clear cell renal cell carcinoma
This single-institution phase II trial evaluates zanzalintinib, a small molecule cMET/VEGFR inhibitor given orally in 28-day cycles, combined with an investigator-chosen bisphosphonate for bone metastases in patients…
NCT07043608 Exploratory - New trial
Head and neck cancer
Phase 2 GdContrast: Gadolinium agent enhances T1 relaxation for improved margin visualization
This prospective study sponsored by Case Comprehensive Cancer Center evaluates whether enhanced pre-operative MRI protocols—including noncontrast, contrast-enhanced, T2 weighted, and T2 SPACE sequences—can predict…
NCT07060261 Exploratory - New trial
Stomach and esophageal cancer
Phase II RP2 HSV-1 oncolytic virus trial with preoperative FLOT in gastroesophageal cancer
This study investigates whether direct tumor injections of RP2, an HSV-1 oncolytic virus, combined with standard FLOT chemotherapy can improve preoperative tumor eradication in patients with resectable stage II-III…
NCT07059611 Exploratory - New trial
Stomach and esophageal cancer
Phase 3 trial of Tislelizumab PD-1 inhibitor in advanced gastric/gastroesophageal adenocarcinoma.
This multi-center, open-label, randomized study by BeiGene compares subcutaneous versus intravenous tislelizumab—with its immune checkpoint blockade—combined with standard chemotherapy for adults with unresectable or…
NCT07043400 Registrational - New trial
Sarcoma and GIST
Phase 1 trial of 5-ALA, tumor‑targeted fluorescent imaging agent in sarcoma
This study evaluates whether oral 5-ALA (20 mg/kg), which is metabolized within tumor cells to emit fluorescence, can improve intraoperative visualization of soft tissue sarcomas in FNCLCC Grade 2 or 3 patients.…
NCT07038278 Exploratory - New trial
Sarcoma and GIST
Phase II Trial: Atezolizumab PD-L1 mAb + Doxorubicin DNA Synthesis Inhibitor in Soft Tissue Sarcoma
This Phase II study evaluates neoadjuvant, concurrent, and adjuvant administration of atezolizumab (a PD-L1 targeted monoclonal antibody) and doxorubicin (a micelle-formulated DNA synthesis inhibitor) combined with…
NCT07049848 Exploratory - New trial
Other cancers
Phase II cemiplimab PD-1 inhibitor trial in incurable NUT carcinoma
This Phase II open-label trial by Northwestern University evaluates cemiplimab—a PD-1 directed monoclonal antibody—in patients with metastatic or unresectable NUT carcinoma lacking standard treatment. Participants…
NCT07050186 Exploratory - New trial
Acute lymphoblastic leukemia
Phase I Asciminib Bcr-Abl Inhibitor Study in Post-Cellular Therapy Ph+ ALL Maintenance
This Phase I trial evaluates asciminib as maintenance therapy for adults with Philadelphia chromosome positive ALL following HSCT or CAR T cell therapy. Patients receive asciminib orally once or twice daily for…
NCT07040982 Exploratory - New trial
Acute lymphoblastic leukemia
Phase 2 Study of Obecabtagene Autoleucel, a CD19-directed CAR-T for High-risk B-cell ALL
This Phase 2 trial at MD Anderson Cancer Center evaluates consolidation therapy with obecabtagene autoleucel, a CD19-directed CAR-T, in patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia…
NCT07053059 Exploratory - New trial
Acute myeloid leukemia and MDS
Pilot Trial: Venetoclax (BCL2 inhibitor) in pediatric AML chemotherapy substitution
Investigators aim to assess whether substituting two cycles of intensive chemotherapy (Ida-FLA and VIA) for standard regimens in intermediate and high risk pediatric AML patients yields comparable or improved…
NCT07059975 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2a trial of NTS071, a TP53 Y220C directed activator
This Phase 1/2a study by Nutshell Therapeutics (Shanghai) Co., LTD. evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in adults with advanced solid tumors harboring a TP53 Y220C…
NCT07060989 First-in-human - New trial
Multiple solid tumors
Phase 1/2 AVZO-1418 trial of investigational tyrosine kinase inhibitor
This Phase 1/2 study evaluates safety, tolerability, pharmacokinetics, and antitumor activity of AVZO-1418, an investigational tyrosine kinase inhibitor, administered intravenously as a monotherapy and in combination…
NCT07038343 First-in-human - New trial
Multiple solid tumors
Phase 1 [18F]CSB-321: Radiolabeled PET imaging agent for mapping immunotherapy response.
This open-label, non-randomized multi-cohort study evaluates up to three doses of [18F]CSB-321—a novel radiolabeled PET imaging agent—in participants with metastatic or unresectable solid tumors, including melanoma,…
NCT07057349 First-in-human - New trial
Multiple solid tumors
Phase 1 Pilot: 111In-ABD147 DLL3-Targeting Imaging Agent for Metastatic Cancer
This pilot trial by Thomas Hope evaluates the safety and imaging performance of 111In-ABD147—a DLL3-targeting agent radiolabeled for SPECT—in patients with metastatic solid tumors, castration-resistant prostate…
NCT07052760 First-in-human - New trial
Multiple solid tumors
Phase 3 Trial: Radiation Therapy (DNA-damaging agent) for High-Risk Bone Metastases
This study evaluates if adding radiation therapy—which uses high energy x-rays to damage cancer cell DNA—to standard care reduces complications in solid tumor patients with asymptomatic high-risk bone metastases.…
NCT06745024 Registrational - New trial
Other blood cancers and transplant
Phase I trial of ICP-248, novel B-cell receptor modulator in mature B-cell malignancies
This study evaluates ICP-248’s safety, tolerability, pharmacokinetics, and preliminary efficacy alone or with CD20-directed antibodies in patients with relapsed/refractory CLL/SLL and mantle cell lymphoma. The trial…
NCT06351527 First-in-human - New trial
Other blood cancers and transplant
Phase II FLAG-Ida trial: fludarabine and cytarabine as DNA synthesis inhibitors with G-CSF boost
This trial evaluates immediate reduced‐intensity total body irradiation followed by donor hematopoietic cell transplant after FLAG-Ida chemotherapy in adults aged 60 and older with adverse-risk AML or high-grade…
NCT07046078 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.